Furthermore, evidence suggests that HS6ST2 is also associated with EMT by interacting with TGF-beta, HIF-1, and estrogen/GPER pathways [24,26,27,28,29], activation of T lymphocytes, and indirectly related with the PD-1, PDL-1 cancer immunotherapy pathway. The gene discussed is HS6ST2; the disease is cancer.